Slide 1

Results of a phase 1 study of

177

Lu-DOTA-HH1 anti body radionuclide

(Betalutin) conjugate for patients with relapsed CD37

non-Hodgkin

lymphomas – Lugano 2015

177Lu-DOTA-HH1 (Betalutin)

• Murine mAb HH1

• Chelate to chemical linker

DOTA

• Beta emitting lutetium-177

(t1/2= 6.7 days)